Oxford Biomedica PLC — Declaration of Voting Results & Voting Rights Announcements 2026

May 7, 2026

National Storage Mechanism | Additional information

RNS Number : 4909D

Oxford Biomedica PLC

07 May 2026

OXB

Result of Annual General Meeting

Oxford, UK - 07 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that all proposed resolutions were duly passed at its Annual General Meeting ("AGM"), held at 3 pm on 07 May 2026 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of AGM by visiting the Company's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2026 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (05 May 2026) there were 120,920,518 ordinary shares of 50 pence each in issue, each carrying one vote per share.

	Resolutions	Votes For (incl. votes at the Chair's discretion)	% of votes cast	Votes Against	% of votes cast	Votes Withheld*	Total votes cast**	Result
	Ordinary resolutions
1	To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2025, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports.	88,022,096	99.98%	14,253	0.02%	149,975	88,036,349	PASS
2	To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) set out at pages 90 to 112 of the Annual Report for the financial year ended 31 December 2025.	77,910,043	88.51%	10,114,321	11.49%	161,960	88,024,364	PASS
3	To reappoint Dr. Roch Doliveux as a Director of the Company.	85,639,916	97.24%	2,431,539	2.76%	114,869	88,071,455	PASS
4	To reappoint Dr. Frank Mathias as a Director of the Company.	86,374,661	98.07%	1,696,798	1.93%	114,865	88,071,459	PASS
5	To reappoint Peter Soelkner as a Director of the Company.	85,669,982	97.27%	2,401,339	2.73%	115,003	88,071,321	PASS
6	To reappoint Professor Dame Kay Davies as a Director of the Company.	85,671,463	97.28%	2,399,858	2.72%	115,003	88,071,321	PASS
7	To reappoint Colin Bond as a Director of the Company.	87,273,801	99.09%	797,520	0.91%	115,003	88,071,321	PASS
8	To reappoint Dr. Lucinda Crabtree as a Director of the Company.	88,047,431	99.97%	24,028	0.03%	114,865	88,071,459	PASS
9	To reappoint Laurence Espinasse as a Director of the Company.	88,046,231	99.97%	25,093	0.03%	115,000	88,071,324	PASS
10	To reappoint Namrata Patel as a Director of the Company.	88,045,714	99.97%	25,610	0.03%	115,000	88,071,324	PASS
11	To reappoint Dr. Heather Preston as a Director of the Company.	85,236,452	96.78%	2,834,872	3.22%	115,000	88,071,324	PASS
12	To reappoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the 2026 AGM until the conclusion of the next AGM of the Company at which the accounts are laid.	88,052,667	99.98%	17,899	0.02%	115,758	88,070,566	PASS
13	To authorise the Audit Committee for and on behalf of the Board to determine the auditors' remuneration.	88,054,882	99.98%	16,778	0.02%	114,664	88,071,660	PASS
14	To authorise the Directors to allot shares.	87,589,834	99.46%	478,537	0.54%	117,953	88,068,371	PASS
	Special resolutions
15	To authorise the Directors to disapply pre-emption rights.	87,247,698	99.07%	819,891	0.93%	118,735	88,067,589	PASS
16	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.	87,103,359	98.90%	968,950	1.10%	114,015	88,072,309	PASS
17	To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.	87,482,967	99.33%	590,744	0.67%	112,613	88,073,711	PASS

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

** Total does not include withheld votes.

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: [email protected]

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE 250 and a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSIFIWEMSEII